Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Sanofi's focus on developing multi-specific therapies is being turned to HIV.
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only through the UK's revamped Cancer Drugs Fund, and at a discounted price.
This year's EASD meeting in Lisbon heard calls to re-categorize type 2 diabetes into novel subsets, as data suggest the approach could lead to better targeted treatments.
Linkage between cardiovascular disease and type 2 diabetes was a top theme of discussion and data presented at this year's EASD meeting in Portugal's capital.
Novo Nordisk's diabetes blockbuster Victoza has finally been approved for national roll-out in China and will thus get a fresh launch there in early January.